Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + marimastat + paclitaxel
- Development stage
- Unknown
- Lead developer
- British Biotech
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination therapy consisting of carboplatin, marimastat, and paclitaxel. Carboplatin and paclitaxel are chemotherapy drugs that destroy quickly dividing cells such as cancer cells. Marimastat is an orally bioavailable broad spectrum matrix metalloproteinase (MMP) inhibitor that prevents the degradation of the basement membrane by these proteases, thereby inhibiting tumor angiogenesis and metastasis. The combination has been studied in phase I clinical trials for patients with advanced non-small cell lung cancer.
- Other names
- PC + marimastatCarboTaxol + marimastat
02
Targets
DNAMMP12 (Macrophage Metalloelastase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on carboplatin + marimastat + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + marimastat + paclitaxel.